Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$3.50-9.79%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · RXRX
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(4.6) + peer(0.2*9.3) + term(0.0) → 3.46% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On November 2, 2026, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. Financial Update On October 15, 2026, the Company estimated that its cash, cash equivalents, and restricted cash balance as of September 30, 2026 was approximately $561 million. Following this offering, we expect our existing cash, cash equivalents and restricted cash will enable us to fund our operating expenses and capital expenditure requirements into 2029. The preliminary cash balance includes approximately $86 million in net proceeds from th…
Results of Operations and Financial Condition. On August 5, 2026, the Company issued a press release announcing its results of operations and financial condition for the second quarter June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On May 6, 2026, the Company issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On February 25, 2026, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On November 5, 2025, the Company issued a press release announcing its results of operations and financial condition for the third quarter September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On August 5, 2025, the Company issued a press release announcing its results of operations and financial condition for the second quarter June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On May 5, 2025, the Company issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On February 28, 2025, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On November 6, 2024, the Company issued a press release announcing its results of operations and financial condition for the third quarter September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On August 8, 2024, the Company issued a press release announcing its results of operations and financial condition for the quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On May 9, 2024, the Company issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On February 27, 2024, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On November 9, 2023, the Company issued a press release announcing its results of operations and financial condition for the third quarter September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On August 8, 2023, Recursion Pharmaceuticals, Inc. (the Company) issued a press release announcing its results of operations and financial condition for the second quarter June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On May 8, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.